BIOMS MEDICAL SECURES LONG-TERM MANUFACTURING AGREEMENTS FOR MULTIPLE SCLEROSIS DRUG

BioMS Medical Corp, a leading developer in the treatment of multiple sclerosis (MS), announced that it has secured long-term manufacturing agreements with two global companies, UCB-Bioproducts and Hospira Worldwide Inc., for its lead MS drug MBP8298. Under the terms of the agreements, UCB-Bioproducts will continue to manufacture the MBP8298 bulk drug and Hospira will fill and finish the drug product into vials for use in patients. These contracts contemplate these companies providing their services through the current pivotal clinical trial for MBP8298 and into commercial production.

CNW Group (http://www.newswire.ca/en/releases/archive/February2006/15/c2512.html)